Skip to main content
Erschienen in: Acta Neurologica Belgica 1/2021

11.11.2020 | Original Article

Identification of a novel missense c.386G > A variant in a boy with the POMGNT1-related muscular dystrophy-dystroglycanopathy

verfasst von: Pouria Mohammadi, Mohammad Ali Daneshmand, Nejat Mahdieh, Mahmoud Reza Ashrafi, Morteza Heidari, Masoud Garshasbi

Erschienen in: Acta Neurologica Belgica | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Muscular dystrophy-dystroglycanopathies are autosomal recessive neurologic disorders, caused by homozygous or compound heterozygous mutations in the POMGNT1 gene-encoding protein O-mannose beta-1,2-N-acetylglucosaminyl transferase. This type of muscular dystrophy is characterized by early-onset muscle weakness, gait ataxia, microcephaly, and developmental delay.We performed whole-exome sequencing to detect the disease-causing variants in a 4 year-old boy. Afterwards, Sanger sequencing was performed to confirm the detected variant in the patient and his family. We evaluated a 4 year-old Iranian boy presented with delayed speech and language development, gait ataxia, global developmental delay, motor delay, neurodevelopmental delay, postnatal microcephaly and strabismus. His parents were first cousins, and the mother had a history of spontaneous abortion. In this study, we report a novel missense c.386G > A; p.(Arg129Gln) variant in the POMGNT1 gene which was confirmed by Sanger sequencing in the patient and segregated with the disease in the family.
Literatur
1.
Zurück zum Zitat Mercuri E, Muntoni F (2013) Muscular dystrophies. The Lancet 381(9869):845–860 Mercuri E, Muntoni F (2013) Muscular dystrophies. The Lancet 381(9869):845–860
2.
Zurück zum Zitat Zamani G et al (2020) The first comprehensive cohort of the duchenne muscular dystrophy in iranian population: mutation spectrum of 314 patients and identifying two novel nonsense mutations. J MolNeurosci 70:1–9 Zamani G et al (2020) The first comprehensive cohort of the duchenne muscular dystrophy in iranian population: mutation spectrum of 314 patients and identifying two novel nonsense mutations. J MolNeurosci 70:1–9
3.
Zurück zum Zitat Zamani G et al (2016) The quality of life in boys with Duchenne muscular dystrophy. NeuromusculDisord 26(7):423–427 Zamani G et al (2016) The quality of life in boys with Duchenne muscular dystrophy. NeuromusculDisord 26(7):423–427
4.
Zurück zum Zitat Wang ET et al (2019) Transcriptome alterations in myotonic dystrophy skeletal muscle and heart. Hum Mol Genet 28(8):1312–1321PubMed Wang ET et al (2019) Transcriptome alterations in myotonic dystrophy skeletal muscle and heart. Hum Mol Genet 28(8):1312–1321PubMed
5.
Zurück zum Zitat Zampatti S et al (2019) Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era. Neurogenetics 20(2):57–64PubMed Zampatti S et al (2019) Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era. Neurogenetics 20(2):57–64PubMed
6.
Zurück zum Zitat Mendell JR, Rodino-Klapac LR, Walker C (2019) Gene therapy clinical trials for duchenne and limb girdle muscular dystrophies: lessons learned, in muscle gene therapy. Springer, Cham, pp 709–725 Mendell JR, Rodino-Klapac LR, Walker C (2019) Gene therapy clinical trials for duchenne and limb girdle muscular dystrophies: lessons learned, in muscle gene therapy. Springer, Cham, pp 709–725
7.
Zurück zum Zitat Scaglioni D et al (2019) P. 145Optimisation of a high–throughput digital script for multiplexed immunofluorescent analysis of sarcolemmaldystrophin-associated protein complex (DPC) and myofibre regeneration in entire transverse sections of muscle biopsies in Duchenne muscular dystrophy. NeuromusculDisord 29:90 Scaglioni D et al (2019) P. 145Optimisation of a high–throughput digital script for multiplexed immunofluorescent analysis of sarcolemmaldystrophin-associated protein complex (DPC) and myofibre regeneration in entire transverse sections of muscle biopsies in Duchenne muscular dystrophy. NeuromusculDisord 29:90
8.
Zurück zum Zitat Xie Z et al (2019) Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of Chinese patients. Orphanet J Rare Dis 14(1):43PubMedPubMedCentral Xie Z et al (2019) Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of Chinese patients. Orphanet J Rare Dis 14(1):43PubMedPubMedCentral
9.
Zurück zum Zitat Taniguchi-Ikeda M et al (2016) Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: a review. Mol Asp Med 51:115–124 Taniguchi-Ikeda M et al (2016) Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: a review. Mol Asp Med 51:115–124
10.
Zurück zum Zitat Diesen C et al (2004) POMGnT1 mutation and phenotypic spectrum in muscle-eye-brain disease. J Med Genet 41(10):e115–e115PubMedPubMedCentral Diesen C et al (2004) POMGnT1 mutation and phenotypic spectrum in muscle-eye-brain disease. J Med Genet 41(10):e115–e115PubMedPubMedCentral
11.
Zurück zum Zitat Peiris TJ et al (2018) Congenital muscular dystrophy-dystroglycanopathy, type A, featuring bilateral retinal dysplasia and vertical angle kappa. J Am AssocPediatrOphthalmol Strabismus 22(3):242-244.e1 Peiris TJ et al (2018) Congenital muscular dystrophy-dystroglycanopathy, type A, featuring bilateral retinal dysplasia and vertical angle kappa. J Am AssocPediatrOphthalmol Strabismus 22(3):242-244.e1
12.
Zurück zum Zitat Qu H-Q et al (2019) Application of ACMG criteria to classify variants in the human gene mutation database. J Hum Genet 64(11):1091–1095PubMed Qu H-Q et al (2019) Application of ACMG criteria to classify variants in the human gene mutation database. J Hum Genet 64(11):1091–1095PubMed
13.
Zurück zum Zitat Brown J, Pirrung M, McCue LA (2017) FQC Dashboard: integrates FastQC results into a web-based, interactive, and extensible FASTQ quality control tool. Bioinformatics 33(19):3137–3139PubMedPubMedCentral Brown J, Pirrung M, McCue LA (2017) FQC Dashboard: integrates FastQC results into a web-based, interactive, and extensible FASTQ quality control tool. Bioinformatics 33(19):3137–3139PubMedPubMedCentral
14.
Zurück zum Zitat Langdon WB (2015) Performance of genetic programming optimised Bowtie2 on genome comparison and analytic testing (GCAT) benchmarks. BioData Min 8(1):1PubMedPubMedCentral Langdon WB (2015) Performance of genetic programming optimised Bowtie2 on genome comparison and analytic testing (GCAT) benchmarks. BioData Min 8(1):1PubMedPubMedCentral
16.
Zurück zum Zitat Thorvaldsdóttir H, Robinson JT, Mesirov JP (2013) Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14(2):178–192PubMed Thorvaldsdóttir H, Robinson JT, Mesirov JP (2013) Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14(2):178–192PubMed
17.
Zurück zum Zitat Koboldt DC et al (2009) VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25(17):2283–2285PubMedPubMedCentral Koboldt DC et al (2009) VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25(17):2283–2285PubMedPubMedCentral
18.
Zurück zum Zitat Ren S, Bertels K, Al-Ars Z (2018) Efficient acceleration of the pair-hmms forward algorithm for gatkhaplotypecaller on graphics processing units. EvolutBioinform 14:1176934318760543 Ren S, Bertels K, Al-Ars Z (2018) Efficient acceleration of the pair-hmms forward algorithm for gatkhaplotypecaller on graphics processing units. EvolutBioinform 14:1176934318760543
19.
Zurück zum Zitat Mi H et al (2017) PANTHER version 11: expanded annotation data from gene ontology and reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 45(D1):D183–D189PubMed Mi H et al (2017) PANTHER version 11: expanded annotation data from gene ontology and reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 45(D1):D183–D189PubMed
22.
Zurück zum Zitat Ma X et al (2015) Rapid decoding of sequence-specific nuclease-induced heterozygous and biallelic mutations by direct sequencing of PCR products. Mol Plant 8(8):1285–1287PubMed Ma X et al (2015) Rapid decoding of sequence-specific nuclease-induced heterozygous and biallelic mutations by direct sequencing of PCR products. Mol Plant 8(8):1285–1287PubMed
23.
Zurück zum Zitat Kaya E et al (2019) Spatial data analysis with R programming for environment. Hum Ecol Risk Assess Int J 25(6):1521–1530 Kaya E et al (2019) Spatial data analysis with R programming for environment. Hum Ecol Risk Assess Int J 25(6):1521–1530
24.
Zurück zum Zitat Yang H, Robinson PN, Wang K (2015) Phenolyzer: phenotype-based prioritization of candidate genes for human diseases. Nat Methods 12(9):841–843PubMedPubMedCentral Yang H, Robinson PN, Wang K (2015) Phenolyzer: phenotype-based prioritization of candidate genes for human diseases. Nat Methods 12(9):841–843PubMedPubMedCentral
25.
Zurück zum Zitat Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–423PubMedPubMedCentral Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–423PubMedPubMedCentral
26.
Zurück zum Zitat Hohenester E (2019) Laminin G-like domains: dystroglycan-specific lectins. CurrOpinStructBiol 56:56–63 Hohenester E (2019) Laminin G-like domains: dystroglycan-specific lectins. CurrOpinStructBiol 56:56–63
27.
Zurück zum Zitat Endo T (2019) Mammalian O-mannosylglycans: Biochemistry and glycopathology. Proc Japan AcadSer B 95(1):39–51 Endo T (2019) Mammalian O-mannosylglycans: Biochemistry and glycopathology. Proc Japan AcadSer B 95(1):39–51
28.
29.
Zurück zum Zitat Sudo A et al (2018) Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage. Hum Mol Genet 27(7):1174–1185PubMedPubMedCentral Sudo A et al (2018) Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage. Hum Mol Genet 27(7):1174–1185PubMedPubMedCentral
30.
Zurück zum Zitat Kuwabara N et al (2016) Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan. ProcNatlAcadSci 113(33):9280–9285 Kuwabara N et al (2016) Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan. ProcNatlAcadSci 113(33):9280–9285
31.
Zurück zum Zitat Xu C et al (2020) N-glycosylated SGK196 suppresses the metastasis of basal-like breast cancer cells. Oncogenesis 9(1):4PubMedPubMedCentral Xu C et al (2020) N-glycosylated SGK196 suppresses the metastasis of basal-like breast cancer cells. Oncogenesis 9(1):4PubMedPubMedCentral
32.
Zurück zum Zitat Xiong H et al (2006) Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of α-dystroglycan. BiochemBiophys Res Commun 350(4):935–941 Xiong H et al (2006) Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of α-dystroglycan. BiochemBiophys Res Commun 350(4):935–941
33.
Zurück zum Zitat Akasaka-Manya K et al (2004) Structure–function analysis of human protein O-linked mannose β1, 2-N-acetylglucosaminyltransferase 1, POMGnT1. BiochemBiophys Res Commun 320(1):39–44 Akasaka-Manya K et al (2004) Structure–function analysis of human protein O-linked mannose β1, 2-N-acetylglucosaminyltransferase 1, POMGnT1. BiochemBiophys Res Commun 320(1):39–44
34.
Zurück zum Zitat Borisovna KO et al (2019) Compound heterozygous POMGNT1 mutations leading to muscular dystrophy-dystroglycanopathy type A3: a case report. BMC Pediatr 19(1):1–8 Borisovna KO et al (2019) Compound heterozygous POMGNT1 mutations leading to muscular dystrophy-dystroglycanopathy type A3: a case report. BMC Pediatr 19(1):1–8
35.
36.
Zurück zum Zitat Jiao H et al (2013) Novel POMGnT1 mutations cause muscle-eye-brain disease in Chinese patients. Mol Genet Genom 288(7–8):297–308 Jiao H et al (2013) Novel POMGnT1 mutations cause muscle-eye-brain disease in Chinese patients. Mol Genet Genom 288(7–8):297–308
37.
Zurück zum Zitat Biancheri R et al (2006) POMGnT1 mutations in congenital muscular dystrophy: genotype-phenotype correlation and expanded clinical spectrum. Arch Neurol 63(10):1491–1495PubMed Biancheri R et al (2006) POMGnT1 mutations in congenital muscular dystrophy: genotype-phenotype correlation and expanded clinical spectrum. Arch Neurol 63(10):1491–1495PubMed
38.
Zurück zum Zitat Saredi S et al (2012) Novel POMGNT1 point mutations and intragenic rearrangements associated with muscle-eye-brain disease. J NeurolSci 318(1–2):45–50 Saredi S et al (2012) Novel POMGNT1 point mutations and intragenic rearrangements associated with muscle-eye-brain disease. J NeurolSci 318(1–2):45–50
39.
Zurück zum Zitat Taniguchi K et al (2003) Worldwide distribution and broader clinical spectrum of muscle–eye–brain disease. Hum Mol Genet 12(5):527–534PubMed Taniguchi K et al (2003) Worldwide distribution and broader clinical spectrum of muscle–eye–brain disease. Hum Mol Genet 12(5):527–534PubMed
40.
Zurück zum Zitat Yiş U et al (2014) Clinical, radiological, and genetic survey of patients with muscle-eye-brain disease caused by mutations in POMGNT1. PediatrNeurol 50(5):491–497 Yiş U et al (2014) Clinical, radiological, and genetic survey of patients with muscle-eye-brain disease caused by mutations in POMGNT1. PediatrNeurol 50(5):491–497
41.
Zurück zum Zitat Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2 0: predicting stability changes upon mutation from the protein sequence or structure. Nucl Acids Res 33(2):W306–W310PubMedPubMedCentral Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2 0: predicting stability changes upon mutation from the protein sequence or structure. Nucl Acids Res 33(2):W306–W310PubMedPubMedCentral
42.
Zurück zum Zitat Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting functional effect of human missense mutations using PolyPhen-2. CurrProtoc Hum Genet 76(1):7.20.1-7.20.41 Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting functional effect of human missense mutations using PolyPhen-2. CurrProtoc Hum Genet 76(1):7.20.1-7.20.41
43.
Zurück zum Zitat Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7):1073PubMed Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7):1073PubMed
44.
Zurück zum Zitat Musso F (2011) A stochastic version of the Eigen model. Bull Math Biol 73(1):151–180PubMed Musso F (2011) A stochastic version of the Eigen model. Bull Math Biol 73(1):151–180PubMed
45.
Zurück zum Zitat Ioannidis NM et al (2016) REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet 99(4):877–885PubMedPubMedCentral Ioannidis NM et al (2016) REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet 99(4):877–885PubMedPubMedCentral
Metadaten
Titel
Identification of a novel missense c.386G > A variant in a boy with the POMGNT1-related muscular dystrophy-dystroglycanopathy
verfasst von
Pouria Mohammadi
Mohammad Ali Daneshmand
Nejat Mahdieh
Mahmoud Reza Ashrafi
Morteza Heidari
Masoud Garshasbi
Publikationsdatum
11.11.2020
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 1/2021
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-020-01527-8

Weitere Artikel der Ausgabe 1/2021

Acta Neurologica Belgica 1/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.